Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 91 full-time employees. The company went IPO on 2009-08-11. The firm is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for CPIX. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: CPIX is a Sell candidate.
CPIX stock price ended at $3.92 on 水曜日, after rising 1.82%
On the latest trading day Feb 18, 2026, the stock price of CPIX rose by 1.82%, climbing from $3.86 to $3.92. During the session, the stock saw a volatility of 4.50%, with prices oscillating between a daily low of $3.78 and a high of $3.95. Notably, trading volume dropped by 37.4K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 149.3K shares were traded, equating to a market value of approximately $58.6M.